About 748,000 results
www.ohsu.edu/xd/health/services/cancer/about-us/druker/Brian Druker, M.D., revolutionized the treatment of cancer through research that
resulted in the first drug to target the molecular defect of a cancer while leaving
healthy cells unharmed. Marketed under the name GleevecŪ, his discovery
turned a once-fatal cancer, Chronic Myeloid Leukemia, into a manageable
https://en.wikipedia.org/wiki/Brian_DrukerBrian J. Druker (born April 30, 1955) is a physician-scientist at Oregon Health &
Science University, in Portland, Oregon. He is the director of OHSU's Knight
Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of
medicine. In 2009, he won the Lasker-DeBakey Clinical Medical Research
Award and the ...
https://en.wikipedia.org/wiki/Peter_DruckerPeter Ferdinand Drucker was an Austrian-born American management
consultant, educator, and author, whose writings contributed to the philosophical
and practical foundations of the modern business corporation. He was also a
leader in the development of management education, he invented the concept
known as ...
www.hhmi.org/scientists/brian-j-drukerBrian J. Druker, MD is an investigator with the Howard Hughes Medical Institute.
https://am.asco.org/dr-brian-j-druker-honored-science-oncology-award-and- lectureMay 25, 2017 ... Brian J. Druker, MD, director of the Knight Cancer Institute at Oregon Health &
Science University, will receive the 2017 Science of Oncology Award and Lecture
https://am.asco.org/dr-brian-j-druker-future-cancer-personalized-prevention- and-detectionJun 6, 2017 ... The future of cancer lies not just with better therapies, but with personalized
prevention and detection using the same molecular techniques that enabled the
development of targeted therapies, Brian J. Druker, MD, of Oregon Health &
Science University, the recipient of the 2017 Science of Oncology Award, ...
https://www.smithsonianmag.com/.../a-triumph-in-the-war-against-cancer- 1784705/Oncologist Brian Druker developed a new treatment for a deadly cancer, leading
to a breakthrough that has transformed medicine.
www.gsd.harvard.edu/urban...and.../druker-traveling-fellowship/Established in 1986 by Ronald M. Druker, Loeb Fellow '76, and by the Trustees
of the Bertram A. Druker Charitable Foundation, this fellowship is open to all
students at the GSD who demonstrate excellence in the design of urban
environments. The fellowship offers students the opportunity to travel in the
United States or ...
people.com/archive/the-miracle-worker-vol-55-no-7/Feb 19, 2001 ... Dr. Brian Druker was afraid he would burn out. As a young oncology fellow at
Harvard's Dana-Farber Cancer Institute in Boston in the mid-1980s, he dreaded
telling patients they had run out of options and having to write condolence letters
to the families of those who had died in his care. The experience ...
www.aacr.org/Membership/Pages/FellowDetailsNoModal.aspx?...22A recognized leader in the field of anti-cancer drug development, Dr. Druker was
instrumental in the development of Gleevec (imatinib), a breakthrough drug that
served as the proof of principle for targeted cancer therapies. Dr. Druker
developed 4G10, an anti-phosphotyrosine antibody essential to Novartis
scientists' kinase ...
Brian J. Druker is a physician-scientist at Oregon Health & Science University, in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute, Jeld-Wen Chair of Leukemia Research, and professor of medicine. Wikipedia
Born: April 30, 1955 (age 62), St. Louis, MO
Education: University of California, San Diego
Awards: Lasker-DeBakey Clinical Medical Research Award, Keio Medical Science Prize, Kettering Prize, Robert Koch Prize
Organization founded: MolecularMD